|
Next-generation-sequencing of advanced melanoma: Which genetic alterations have an impact on systemic therapy response? |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Roche Pharma AG |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Roche Pharma AG |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Philogen; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Philogen; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |